文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一项关于被误诊为肠易激综合征的非恶性、器质性胃肠道疾病患病率的系统评价和荟萃分析。

A systematic review and meta-analysis on the prevalence of non-malignant, organic gastrointestinal disorders misdiagnosed as irritable bowel syndrome.

机构信息

Department of Gastroenterology, Lincoln County Hospital, Greetwell Road, Lincoln, LN2 5QY, UK.

Community and Health Research Unit, School of Health and Social Care, University of Lincoln, Lincoln, LN6 7TS, UK.

出版信息

Sci Rep. 2022 Feb 4;12(1):1949. doi: 10.1038/s41598-022-05933-1.


DOI:10.1038/s41598-022-05933-1
PMID:35121775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8817019/
Abstract

Treatable gastrointestinal disorders in patients with symptoms typical for irritable bowel syndrome (IBS) may be overlooked. The prevalence of five gastrointestinal conditions-bile acid diarrhoea (BAD), carbohydrate malabsorption (CM), microscopic colitis (MC), pancreatic exocrine insufficiency (PEI) and small intestinal bacterial overgrowth (SIBO) was systematically assessed from studies including consecutive patients meeting diagnostic criteria for IBS. 4 databases were searched from 1978 to 2020. Studies were included if they evaluated the prevalence of these conditions in secondary healthcare setting. Estimated pooled rates were calculated and statistical heterogeneity between studies was evaluated using Q and I statistics. Seven studies (n = 597) estimated the pooled prevalence for BAD as 41% (95% CI 29-54). 17 studies (n = 5068) estimated that of MC as 3% (95% CI 2-4%). Two studies (n = 478) suggested a rate of 4.6% (range: 1.8-6.1%) for PEI. Using breath testing, 26 studies (n = 6700) and 13 studies (n = 3415) estimated the prevalence of lactose and fructose malabsorption as 54% (95% CI 44-64%) and 43% (95% CI 23-62%); 36 studies (n = 4630) and 22 studies (n = 2149) estimated that of SIBO as 49% (95% CI 40-57%) with lactulose and 19% (95% CI 13-27%) with glucose. Rates of all conditions were significantly higher than in healthy controls. A significant proportion of patients presenting to secondary care with IBS have an organic condition which may account for their symptoms. Failure to exclude such conditions will deny patients effective treatment.

摘要

在有肠易激综合征(IBS)典型症状的患者中,可能会忽视可治疗的胃肠道疾病。通过纳入符合 IBS 诊断标准的连续患者的研究,系统性评估了五种胃肠道疾病的患病率,包括胆汁酸腹泻(BAD)、碳水化合物吸收不良(CM)、显微镜结肠炎(MC)、胰腺外分泌功能不全(PEI)和小肠细菌过度生长(SIBO)。从 1978 年到 2020 年,4 个数据库被检索。如果研究评估了这些疾病在二级医疗保健环境中的患病率,则纳入研究。使用 Q 和 I 统计量评估研究之间的统计异质性,并计算估计的总患病率。7 项研究(n=597)估计 BAD 的总患病率为 41%(95%CI 29-54)。17 项研究(n=5068)估计 MC 的总患病率为 3%(95%CI 2-4%)。2 项研究(n=478)提示 PEI 的发生率为 4.6%(范围:1.8-6.1%)。使用呼吸测试,26 项研究(n=6700)和 13 项研究(n=3415)估计乳糖和果糖吸收不良的患病率分别为 54%(95%CI 44-64%)和 43%(95%CI 23-62%);36 项研究(n=4630)和 22 项研究(n=2149)估计 SIBO 的患病率分别为 49%(95%CI 40-57%),用乳果糖和 19%(95%CI 13-27%),用葡萄糖。所有疾病的发生率均明显高于健康对照组。在二级医疗机构就诊的 IBS 患者中有相当一部分存在器质性疾病,这些疾病可能是他们症状的原因。如果不排除这些疾病,将使患者无法获得有效治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/1102a173eddf/41598_2022_5933_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/621dd126d2e6/41598_2022_5933_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/3bc4c44c9b1f/41598_2022_5933_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/a8f96c0f75ee/41598_2022_5933_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/19c550e7c77e/41598_2022_5933_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/016af88bf424/41598_2022_5933_Fig5a_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/1102a173eddf/41598_2022_5933_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/621dd126d2e6/41598_2022_5933_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/3bc4c44c9b1f/41598_2022_5933_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/a8f96c0f75ee/41598_2022_5933_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/19c550e7c77e/41598_2022_5933_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/016af88bf424/41598_2022_5933_Fig5a_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e4b/8817019/1102a173eddf/41598_2022_5933_Fig6_HTML.jpg

相似文献

[1]
A systematic review and meta-analysis on the prevalence of non-malignant, organic gastrointestinal disorders misdiagnosed as irritable bowel syndrome.

Sci Rep. 2022-2-4

[2]
Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies.

Am J Gastroenterol. 2020-2

[3]
Microscopic colitis and small intestinal bacterial overgrowth--diagnosis behind the irritable bowel syndrome?

Rev Med Chir Soc Med Nat Iasi. 2012

[4]
Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea.

Aliment Pharmacol Ther. 2015-7

[5]
[Estimation of small intestinal bacterial overgrowth in patients with constipation and diarrhea irritable bowel syndrome].

Pol Merkur Lekarski. 2014-5

[6]
The overlap between irritable bowel syndrome and organic gastrointestinal diseases.

Lancet Gastroenterol Hepatol. 2021-2

[7]
Breath tests and irritable bowel syndrome.

World J Gastroenterol. 2014-6-28

[8]
SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.

Health Technol Assess. 2013-12

[9]
Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome.

Aliment Pharmacol Ther. 2009-6-30

[10]
Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis.

J Gastroenterol. 2018-5-14

引用本文的文献

[1]
The road to Rome IV and beyond: Evolution, refinements and future considerations for the Rome criteria for functional gastrointestinal disorders.

Indian J Gastroenterol. 2025-7-4

[2]
The Role of the Nurse in the Management of Irritable Bowel Syndrome: A Narrative Review.

Transl Med UniSa. 2023-12-22

[3]
Common misconceptions and controversies in the management of irritable bowel syndrome.

Nat Rev Gastroenterol Hepatol. 2025-4-25

[4]
European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidence-based recommendations.

United European Gastroenterol J. 2025-2

[5]
Unplanned 30-Day Readmissions After Hospitalization for Irritable Bowel Syndrome.

Cureus. 2024-7-14

[6]
Analysis of quality of life in patients after transgastric natural orifice transluminal endoscopic gallbladder-preserving surgery.

World J Gastrointest Endosc. 2024-6-16

[7]
Fecal Coprococcus, hidden behind abdominal symptoms in patients with small intestinal bacterial overgrowth.

J Transl Med. 2024-5-25

[8]
Follow-Up of Microscopic Colitis Patients and Diarrhea Controls at 1 Year.

Gastro Hep Adv. 2024

[9]
Diagnostic strategy of irritable bowel syndrome: a low- and middle-income country perspective.

Intest Res. 2024-7

[10]
Getting the BS out of Irritable Bowel Syndrome with Diarrhea (IBS-D): Let's Make a Diagnosis.

Curr Gastroenterol Rep. 2024-1

本文引用的文献

[1]
ACG Clinical Guideline: Management of Irritable Bowel Syndrome.

Am J Gastroenterol. 2021-1-1

[2]
Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.

Lancet Gastroenterol Hepatol. 2020-10-2

[3]
High prevalence of primary bile acid diarrhoea in patients with functional diarrhoea and irritable bowel syndrome-diarrhoea, based on Rome III and Rome IV criteria.

EClinicalMedicine. 2020-7-15

[4]
Diagnostic Yield of Colonoscopy in Patients With Symptoms Compatible With Rome IV Functional Bowel Disorders.

Clin Gastroenterol Hepatol. 2022-2

[5]
Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies.

Am J Gastroenterol. 2020-2

[6]
Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis.

Lancet Gastroenterol Hepatol. 2019-12-16

[7]
Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption.

Gastroenterology. 2019-12-14

[8]
Is abnormal 25 g fructose breath test a predictor of symptomatic response to a low fructose diet in irritable bowel syndrome?

Clin Nutr. 2020-4

[9]
Prevalence of Organic Colonic Lesions by Colonoscopy in Patients Fulfilling ROME IV Criteria of Irritable Bowel Syndrome.

JNMA J Nepal Med Assoc. 2018

[10]
Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition.

Gut. 2018-4-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索